Table 3 Survival-related prognostic factors for the 87 patients
From: Pathological evaluation of neoadjuvant chemotherapy in advanced gastric cancer
Variable | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
n = 87(%) | Median survival (months) | p value | HR | 95% CI | p value | |
Sex | 0.542 | |||||
Male | 66 (75.9) | 76.0 | 1 (Ref) | |||
Female | 21 (24.1) | – | 1.552 | 0.637–3.777 | 0.333 | |
Tumor location | 0.009 | 0.104 | ||||
Upper body | 16 (18.4) | 57.5 | 1 (Ref) | – | – | |
Middle body | 27 (31.0) | – | 0.347 | 0.132–0.915 | 0.032 | |
Lower body | 41 (47.1) | – | 0.532 | 0.216–1.310 | 0.17 | |
Diffuse type | 3 (3.4) | 15.0 | 1.193 | 0.254–5.597 | 0.823 | |
Preoperative TNM stage | 0.361 | 1.063 | 0.521–2.168 | 0.867 | ||
II | 41 (47.1) | 57.5 | 1 (Ref) | |||
III+IV | 46 (52.9) | 97.5 | ||||
Lauren classification | 0.002 | 0.025 | ||||
Intestinal | 30 (34.5) | – | ||||
Diffuse | 49 (56.3) | 38.0 | 3.843 | 1.443–10.237 | 0.007 | |
Mixed | 8 (9.2) | 22.0 | 2.624 | 0.698–9.863 | 0.153 | |
Vascular invasion | 0.342 | |||||
Yes | 12 (13.8) | 46.5 | 0.908 | 0.370–2.232 | 0.834 | |
No | 75 (86.2) | – | 1 (Ref) | |||
Tumor differentiation | 0.269 | |||||
Well-/median differentiated | 15 (17.2) | 76.0 | ||||
Poorly differentiated/mucinous or signet ring cell carcinoma | 72 (82.8) | 63.0 | 1.429 | 0.455–4.486 | 0.541 | |
ypTNM | 0.001 | < 0.001 | ||||
0+I | 16 (18.4) | – | 1 (Ref) | |||
II | 40 (46.0) | – | 3.533 | 1.886–6.617 | < 0.001 | |
III | 31 (35.6) | 19.0 | 3.576 | 1.908–6.703 | < 0.001 | |
GHR | 0.022 | |||||
≥ 50% | 44 (50.6) | – | 1 (Ref) | |||
< 50% | 43 (49.4) | 34.5 | 1.171 | 0.653–2.764 | 0.689 | |
GHR | 0.013 | |||||
≥ 2/3 | 30 (34.5) | – | 1 (Ref) | |||
< 2/3 | 57 (65.5) | 46.5 | 1.654 | 0.680–4.024 | 0.267 | |
GHR | 0.028 | |||||
≥ 90% | 15 (17.2) | – | 1 (Ref) | |||
< 90% | 72 (82.8) | 54.0 | 0.998 | 0.254–3.917 | 0.998 | |